Kam Balaggan, BSc (Hons), MBBS, MRCOphth, PhD
Dr. Balaggan is a Vitreoretinal Surgery fellow at Moorfields Eye Hospital National Health Service (NHS) Foundation Trust in London and an honorary research fellow in the Department of Genetics at University College London Institute of Ophthalmology. He completed his residency and vitreoretinal surgery fellowship (ASTO) at Moorfields Eye Hospital and a PhD in Genetics from University College London.
Dr. Balaggan has authored 28 peer-reviewed publications, 12 as first-author that have appeared in journals including Nature Medicine, New England Journal of Medicine, Ophthalmology and British Journal of Ophthalmology. He is also a peer-reviewer for six medical science journals and has frequently lectured on his research performed at Moorfields Eye Hospital and University College London Institute of Ophthalmology.
Dr. Balaggan was a co-investigator in the world’s first gene therapy trial for an inherited retinopathy (New England Journal of Medicine 2008), and more recently a key investigator in the first randomized clinical evaluation of subconjunctival bevacizumab for new onset corneal neovascularization (British Journal of Ophthalmology, 2012). While studying at UCL, his doctoral work primarily focused upon developing novel gene therapy approaches to targeting choroidal neovascularization.
Dr. Balaggan is the recipient of six local, national and international prizes in recognition of the quality of his research, including the prestigious Moorfields Eye Hospital Arthur Steele Research Medal for Best Research by a Resident, Royal College of Ophthalmologists Foulds Trophy, and Best Paper Presentation American Academy of Ophthalmology. He is a member of the Royal College of Ophthalmologists, The Association for Research in Vision and Ophthalmology, and The American Academy of Ophthalmology.